OMP-52M51
52M51-002
Phase 1 small_molecule completed
Quick answer
OMP-52M51 for Relapsed or Refractory Solid Tumors is a Phase 1 program (small_molecule) at Mereo BioPharma Group plc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Mereo BioPharma Group plc
- Indication
- Relapsed or Refractory Solid Tumors
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed